A detailed history of Cwm, LLC transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Cwm, LLC holds 36,013 shares of LRMR stock, worth $154,495. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,013
Previous 32,652 10.29%
Holding current value
$154,495
Previous $94,000 23.4%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 15, 2025

BUY
$2.88 - $5.1 $9,679 - $17,141
3,361 Added 10.29%
36,013 $116,000
Q2 2025

Jul 25, 2025

BUY
$1.71 - $3.25 $37,531 - $71,331
21,948 Added 205.04%
32,652 $94,000
Q1 2025

May 01, 2025

BUY
$2.15 - $4.18 $22,908 - $44,537
10,655 Added 21744.9%
10,704 $23,000
Q4 2024

Feb 04, 2025

BUY
$3.8 - $9.29 $121 - $297
32 Added 188.24%
49 $0
Q3 2024

Oct 08, 2024

BUY
$6.3 - $10.68 $25 - $42
4 Added 30.77%
17 $0
Q2 2024

Jul 09, 2024

BUY
$6.33 - $9.89 $75 - $118
12 Added 1200.0%
13 $0
Q1 2024

Apr 05, 2024

BUY
$4.2 - $13.28 $4 - $13
1 New
1 $0
Q3 2023

Oct 11, 2023

BUY
$3.08 - $4.49 $264 - $386
86 New
86 $0

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $186M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.